<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        3008200140
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Pevas
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        PRASUGREL
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        Store below 30°C , Protect from light and moisture
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        157.5
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="UNITED PHARMACEUTICAL COMPANY" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            UNITED PHARMACEUTICAL COMPANY
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 359]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Cigalah Group
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            MS Pharma Saudi (MSPS)
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        B01AC22
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Pevas, which contains the active substance prasugrel, belongs to a group of medicines called anti-platelet agents. Platelets are very small cell particles that circulate in the blood. When a blood vessel is damaged, for example if it is cut, platelets clump together to help form a blood clot (thrombus). Therefore, platelets are essential to help stop bleeding. If clots form within a hardened blood vessel such as an artery they can be very dangerous as they can cut off the blood supply, causing a heart attack (myocardial infarction), stroke or death. Clots in arteries supplying blood to the heart may also reduce the blood supply, causing unstable angina (a severe chest pain).</p><p>Pevas inhibits the clumping of platelets and so reduces the chance of a blood clot forming.</p><p>You have been prescribed Pevas because you have already had a heart attack or unstable angina and you have been treated with a procedure to open blocked arteries in the heart. You may also have had one or more stents placed to keep open a blocked or narrowed artery supplying blood to the heart. Pevas reduces the chances of you having a further heart attack or stroke or of dying from one of these atherothrombotic events. Your doctor will also give you acetylsalicylic acid (e.g. aspirin), another anti-platelet agent.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take Pevas </strong></p><p>- If you are allergic (hypersensitive) to prasugrel or any of the other ingredients of Pevas. An allergic reaction may be recognized as a rash, itching, a swollen face, swollen lips or shortness of breath. If this has happened to you, tell your doctor <strong>immediately</strong>.</p><p>- If you have a medical condition that is currently causing bleeding, such as bleeding from your stomach or intestines.</p><p>- If you have ever had a stroke or a transient ischemic attack (TIA).</p><p>- If you have severe liver disease.</p><p><strong>Warnings and precautions </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Before you are taking Pevas: </strong></p><p>Talk to your doctor before taking Pevas.</p><p>You should tell your doctor before taking Pevas if any of the situations mentioned below apply to you:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have an increased risk of bleeding such as:</p><p>- age of 75 years or older. Your doctor should prescribe a daily dose of 5 mg as there is a greater risk of bleeding in patients older than 75 years</p><p>- a recent serious injury</p><p>- recent surgery (including some dental procedures)</p><p>- recent or recurrent bleeding from the stomach or intestines (e.g. a stomach ulcer or colon polyps)</p><p>- body weight of less than 60 kg. Your doctor should prescribe a daily dose of 5 mg of Pevas if you weigh less than 60 kg</p><p>- renal (kidney) disease or moderate liver problems</p><p>- taking certain types of medicines (see &lsquo;Taking other medicines&rsquo; below)</p><p>- planned surgery (including some dental procedures) in the next seven days. Your doctor may wish you to stop taking Pevas temporarily due to the increased risk of bleeding</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have had allergic reactions (hypersensitivity) to clopidogrel or any other anti-platelet agent</p><p>please tell your doctor before starting treatment with Pevas. If you then take Pevas and experience allergic reactions that may be recognized as a rash, itching, a swollen face, swollen lips or shortness of breath you need to tell your doctor <strong>immediately. </strong></p><p>&nbsp;</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>While you are taking Pevas: </strong></p><p>You should tell your doctor immediately if you develop a medical condition called Thrombotic Thrombocytopaenic Purpura (or TTP) that includes fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice) (see section 4 &lsquo;Possible side effects&rsquo;).</p><p>&nbsp;</p><p><strong>Children and adolescents </strong></p><p>Pevas should not be used in children and adolescents below 18 years of age.</p><p>&nbsp;</p><p><strong>Other medicines and Pevas </strong></p><p>Tell your doctor if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription, dietary supplements and herbal remedies.</p><p>&nbsp;</p><p>It is particularly important to tell your doctor if you are being treated with:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; clopidogrel (an anti-platelet agent),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; warfarin (an anti-coagulant),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ldquo;non steroidal anti inflammatory drugs&rdquo; for pain and fever (such as ibuprofen, naproxen, etoricoxib).</p><p>&nbsp;</p><p>If given together with Pevas these medicines may increase the risk of bleeding.</p><p>Tell your doctor if you are taking morphine or other opioids (used to treat severe pain).</p><p>Only take other medicines while you are on Pevas if your doctor tells you that you can.</p><p>&nbsp;</p><p><strong>Pregnancy and breast-feeding </strong></p><p>Tell your doctor if you become pregnant or are trying to become pregnant while you are taking Pevas. You should use Pevas only after discussing with your doctor the potential benefits and any potential risks to your unborn child.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p>&nbsp;</p><p><strong>Driving and using machines </strong></p><p>Pevas is unlikely to affect your ability to drive or use machines.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>&nbsp;</p><p>The usual dose of Pevas is 5 mg per day. You will start the treatment with a single dose of 60 mg.</p><p>If you weigh less than 60 kg or are more than 75 years of age, the dose is 5 mg Pevas per day.</p><p>Your doctor will also tell you to take acetylsalicylic acid- (s)he will tell you the exact dose to take (usually between 75 mg and 325 mg daily).</p><p>&nbsp;</p><p>You may take Pevas with or without food. Take your dose at around the same time every day. Do not break or crush the tablet.</p><p>&nbsp;</p><p>It is important that you tell your doctor, dentist and pharmacist, that you are taking Pevas.</p><p>&nbsp;</p><p><strong>If you take more Pevas than you should </strong></p><p>Contact your doctor or hospital straight away, as you may be at risk of excessive bleeding. You should show the doctor your pack of Pevas.</p><p>&nbsp;</p><p><strong>If you forget to take Pevas </strong></p><p>If you miss your scheduled daily dose, take Pevas when you remember. If you forget your dose for an entire day, just resume taking Pevas at its usual dose the next day. Do not take a double dose to make up for a forgotten dose</p><p>&nbsp;</p><p><strong>If you stop taking Pevas </strong></p><p>Do not stop taking Pevas without consulting your doctor; if you stop taking Pevas too soon, your risk of a heart attack may be higher.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>&nbsp;</p><p>Contact your doctor immediately if you notice any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden numbness or weakness of the arm, leg or face, especially if only on one side of the body.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden confusion, difficulty speaking or understanding others.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden difficulty in walking or loss of balance or co-ordination.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden dizziness or sudden severe headache with no known cause.</p><p>All of the above may be signs of a stroke. Stroke is an uncommon side effect of Pevas in patients who have never had a stroke or transient ischaemic attack (TIA).</p><p>&nbsp;</p><p>Also contact your doctor immediately if you notice any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fever and bruising under the skin that may appear as red pinpoint dots, with or without unexplained extreme tiredness, confusion, yellowing of the skin or eyes (jaundice). (see section 2 &lsquo;What you need to know before you take Pevas&rsquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A rash, itching, or a swollen face, swollen lips/tongue, or shortness of breath. These may be signs of a severe allergic reaction (see section 2 &lsquo;What you need to know before you take Pevas&rsquo;).</p><p>&nbsp;</p><p>&nbsp;</p><p>Tell your doctor <strong>promptly </strong>if you notice any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in your urine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from your rectum, blood in your stools or black stools.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Uncontrollable bleeding, for example from a cut.</p><p>&nbsp;</p><p>All of the above may be signs of bleeding, the most common side effect with Pevas. Although uncommon, severe bleeding can be life-threatening.</p><p>&nbsp;</p><p>Common side effects (may affect up to 1 in 10 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding in the stomach or bowels</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding from a needle puncture site</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nose bleeds</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Small red bruises on the skin (ecchymosis)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hematoma (bleeding under the skin at the site of an injection, or into a muscle, causing swelling)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low hemoglobin or red blood cell count (anemia)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bruising</p><p>&nbsp;</p><p>Uncommon side effects (may affect up to 1 in 100 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reaction (rash, itching, swollen lips/tongue, or shortness of breath)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Spontaneous bleeding from the eye, rectum, gums or in the abdomen around the internal organs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Bleeding after surgery</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Coughing up blood</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood in stools</p><p>&nbsp;</p><p>Rare side effects (may affect up to 1 in 1,000 people)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood platelet count</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Subcutaneous hematoma (bleeding under the skin causing a swelling)</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date, which is stated on the blister and carton after EXP.</p><p>The expiry date refers to the last day of that month.</p><p>Do not store above 30&deg;C</p><p>Store in the original package in order to protect from air and moisture.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- The active substance is prasugrel.</p><p>Pevas 5 mg: Each tablet contains 5 mg of prasugrel (as hydrochloride).</p><p>Pevas 10 mg: Each tablet contains 10 mg of prasugrel (as hydrochloride).</p><p>&nbsp;</p><p>- The other ingredients are:</p><p>Microcrystalline cellulose, Spray Dried Mannitol ,croscarmellose sodium, hydroxypropyl methylcellulose 5cp, magnesium stearate, opadry White OYL 28900 and yellow iron oxide, (yellow iron oxide for Pevas 10mg)</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Pevas 5 mg: The tablets are Yellow caplet flat tablets, 
embossed with “U33” from one side and plain from other side
Pevas 10 mg: The tablets are Beige caplet biconvex shape,
embossed with “T10” from one side and plain from other side.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>MS Pharma Saudi,</p><p>Riyadh, Kingdome Saudi Arabia.</p><p>info-ksa@mspharma.com</p><p>&nbsp;</p><p><strong>Manufacturer by:</strong></p><p>&nbsp;United Pharmaceutical Mfg. Co. Ltd.-Jordan for MS Pharma-Saudi</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Feb-2020
SPM190357

            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يحتوي <strong>بيڤاس </strong>على المادة الفعالة براسوجريل، والتي تنتمي إلى مجموعة من الأدوية تُسمّى مضادات الصفائح الدموية. الصفائح الدموية عبارة عن جزيئات خلوية صغيرة تسبح في الدم. عندما يحدث تلف في الوعاء الدموي؛ قطع على سبيل المثال، فإن الصفائح الدموية تتجمع معًا لتساعد في تكوين الجلطة الدموية. وبناءً على ذلك فإن دور الصفائح الدموية في غاية الأهمية من أجل إيقاف النزيف. إذا تكونت الجلطات بفعل الاصطدام بالشرايين المتصلّبة، فإن ذلك قد يسبب مشاكل خطيرة، حيث بإمكان الجلطة إيقاف الإمداد الدموي مما يتسبب في سكتة قلبية (احتشاء عضلة القلب) أو جلطة دماغية وقد تؤدي إلى الموت. يتسبب تكون الجلطات في الأوعية الدموية التي تمد القلب بالدم بنقص في الإمداد الدموي للقلب مما ينتج عنه ذبحة صدرية (ألم شديد في الصدر).</p><p dir="RTL">يقوم <strong>بيڤاس </strong>بتثبيط قدرة الصفائح الدموية على التجمع، مما يقلل من فرص تكون الجلطات الدموية.</p><p dir="RTL">تم وصف <strong>بيڤاس </strong>لك لأنك قد أُصبت بالفعل بسكتة قلبية أو ذبحة صدرية، حيث تتم معالجتك عبر فتح الشرايين المسدودة في القلب. كما أنه من الممكن أنك قد خضعت لتركيب دعامة أو أكثر لإبقاء الأوعية الدموية التي تمد القلب بالدم مفتوحة. يقلل <strong>بيڤاس </strong>من الفرص المحتملة لإصابتك بسكتة قلبية أو جلطة دماغية أخرى كما يقلل من احتمالية الموت بسبب هذه الجلطات. سيقوم الطبيب بإعطائك أحد مضادات الصفائح الدموية أيضًا وهو حمض الأسيتيل سالسيليك (أسبرين).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول <strong>بيڤاس </strong>إذا كنت:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لديك حساسية مفرطة لمادة براسوجريل أو لأي مكونات أخرى في هذا الدواء. يظهر رد الفعل التحسسي في صورة طفح جلدي وشعور بالحكّة وتورُّم الوجه والشفاه أو قصر في النفس. <strong>يجب إبلاغ الطبيب</strong> <strong>فور</strong> ملاحظة ظهور أي من هذه الأعراض.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تعاني من حالة مرضية تتسبب في وجود نزيف مثل النزيف من المعدة أو الأمعاء.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق لك الإصابة بجلطة دماغية أو نوبة إقفارية عابرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;سبق لك الإصابة بأي مشكلة في الكبد.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>التحذيرات والاحتياطات:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>قبل تناولك بيڤاس:</strong></p><p dir="RTL">استشر طبيبك قبل تناول هذا الدواء.</p><p dir="RTL">يجب عليك استشارة الطبيب إذا كانت أي من الحالات المذكورة أدناه تنطبق عليك:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت أكثر عرضة لخطر النزيف، مثل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت تبلغ من العمر 75 عاما أو أكثر. ينبغي أن يصف لك الطبيب جرعة يومية مقدارها 5 ملغم لأن خطر النزيف يزيد عند المرضى الذين تزيد أعمارهم عن 75 سنة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت قد عانيت مؤخرا من إصابة خطيرة.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إن كنت قد أجريت مؤخرًا عملية جراحية (بما في ذلك عمليات الأسنان).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من نزيف حالي أو متكرر من المعدة أو الأمعاء (على سبيل المثال: قرحة معدية أو زوائد قولونية).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان وزنك أقل من 60 كجم. ينبغي أن يصف لك الطبيب جرعة يومية مقدارها 5 ملغم إذا كان وزنك أقل من 60 كغم.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشاكل في الكلية أو مشاكل متوسطة في الكبد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتلقى أدوية معينة غير هذا الدواء. (انظر الفقرة التالية &quot;تناول أدوية أخرى&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخطط لإجراء عملية جراحية في الأسبوع القادم (بما في ذلك عمليات الأسنان). سيخبرك طبيبك حينها بضرورة التوقف عن تناول هذا الدواء لفترة مؤقتة لأنه قد يزيد من خطر النزيف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يجب عليك إخبار الطبيب قبل البدء بتناول هذا الدواء إذا كان قد سبق لك الإصابة بالتحسس المفرط من مادة كلوبيدوجريل أو أي دواء مضاد للصفائح الدموية. <strong>يجب إبلاغ الطبيب فور</strong> ظهور أي رد فعل تحسُّسِي والذي يظهر في صورة طفح جلدي وشعور بالحكّة وتورم الوجه والشفاه أو قصر في النفس.</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>أثناء تناولك بيڤاس:</strong></p><p dir="RTL">يجب عليك إبلاغ الطبيب بأسرع وقت ممكن إذا أصبت بحالة تسمى &quot;الفُرْفُرِيَّة القَليلَة الصُّفَيحات التجلطيّة&quot; وهي عبارة عن ارتفاع في درجة الحرارة وظهور كدمات تحت الجلد، قد تبدو مثل نقاط صغيرة حمراء، مع أو بدون تعب شديد غير مبرر، بالإضافة إلى الشعور بالتشتت مع اصفرار الجلد أو العينين (يرقان). (انظر الفقرة الرابعة &quot;الأعراض الجانبية المحتملة&quot;).</p><p dir="RTL"><strong>الأطفال والمراهقين:</strong></p><p dir="RTL">لا يُسمح باستخدام <strong>بيڤاس </strong>مع الأطفال والمراهقين تحت سن 18 سنة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تناول أدوية أخرى مع بيڤاس:</strong></p><p dir="RTL">يجب عليك إخبار الطبيب إذا كنت تتناول أدوية أو تناولت مؤخرًا بعض الأدوية أو تنوي تناول أي دواء آخر، بما في ذلك الأدوية التي تأتي بدون وصفة طبية والمكملات الغذائية والأعشاب الطبية أيضا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب عليك إخبار الطبيب إن كنت تتناول أي من هذه الأدوية على وجه التحديد:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كلوبيدوجريل (دواء مضاد للصفائح الدموية).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وارفرين (دواء مضاد للتجلط).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الغير استيرويدية المضادة للالتهاب التي تؤخذ من أجل الألم والحرارة (مثل دواء إبيبروفين ونابروكسين وإيتوريكوكسيب).</p><p dir="RTL">إذا تم تناول أي من هذه الأدوية مع <strong>بيڤاس </strong>فسيكون المريض أكثر عرضة للنزيف.</p><p dir="RTL">يجب عليك إخبار الطبيب إن كنت تتناول دواء مورفين أو أي من الأدوية التي تنتمي لمجموعة الأفيونات (تستخدم في علاج الألم الشديد).</p><p dir="RTL">لا يمكنك تناول أي دواء آخر مع <strong>بيڤاس </strong>إلا بعد استشارة الطبيب وسماحه لك ذلك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية:</strong></p><p dir="RTL">يجب عليكٍ إبلاغ الطبيب عند حصول الحمل أو محاولة الحمل أثناء تناول دواء <strong>بيڤاس</strong>.</p><p dir="RTL">لا ينصح بتناول <strong>بيڤاس </strong>إلا بعد استشارة الطبيب حول الفوائد المتوقعة والمخاطر المحتملة على الجنين.</p><p dir="RTL">يجب استشارة الطبيب أو الصيدلي قبل تناول هذا الدواء في حالة السيدات الحوامل أو السيدات التي تقوم بالرضاعة الطبيعية أو في حالات الاعتقاد بالحمل أو التخطيط لحدوث الحمل.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات:</strong></p><p dir="RTL">لا يؤثر <strong>بيڤاس </strong>على القدرة على القيادة أو استخدام الآلات.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب عليك تناول هذا الدواء وفقًا لتعليمات الطبيب. يرجى التوجه بالسؤال للطبيب أو الصيدلي في حالة عدم تأكدك.</p><p dir="RTL">الجرعة المعتادة لعقار <strong>بيڤاس </strong>هي 5 ملغم في اليوم. ستبدأ العلاج بجرعة واحدة مقدارها 60 ملغم. وفي حالة كان وزنك أقل من 60 كجم أو تبلغ من العمر أكثر من 75 عاما، فإن الجرعة المحددة لك هي 5 ملغم في اليوم. سيخبرك الطبيب أيضا بأخذ عقار حمض الأسيتيل سالسيليك وبالجرعة المحددة (تتراوح الجرعة في الغالب بين 75 ملغم و325 ملغم في اليوم).</p><p dir="RTL">يمكنك تناول <strong>بيڤاس </strong>مع الطعام أو بدونه. تناول الجرعة المحددة لك في نفس الموعد كل يوم. لا تقم بكسر أو طحن أقراص الدواء.</p><p dir="RTL">من المهم أن تبلغ طبيبك أو طبيب الأسنان أو الصيدلي بأنك تتناول دواء <strong>بيڤاس</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا تناولت جرعات من دواء بيڤاس أكثر من الموصى بها:</strong></p><p dir="RTL">يجب عليك سرعة التوجه إلى الطبيب أو المستشفى على الفور لأنه من المحتمل أنك صرت أكثر عرضة للنزيف الحاد. ينبغي عليك إظهار عبوة الدواء الخاصة بك للطبيب.&nbsp;&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا نسيت تناول بيڤاس:</strong></p><p dir="RTL">إذا فاتك موعد الجرعة اليومية من الدواء، فيمكنك تناولها وقت تذكرك. أما في حالة إن كنت نسيت تناول جرعتك من الدواء طول اليوم، فيمكنك حينها متابعة تناول الدواء بالجرعة اليومية الاعتيادية في اليوم التالي. لا تتناول جرعة مزدوجة لتعويض جرعتك الفائتة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>إذا توقفت عن تناول بيڤاس:</strong></p><p dir="RTL">لا تتوقف عن تناول هذا الدواء إلا بعد استشارة الطبيب. في حالة توقفك عن تناول هذا الدواء في وقت مبكر جدًا فإنك ستكون أكثر عرضة للإصابة بسكتة قلبية.</p><p dir="RTL">يرجى استشارة الطبيب أو الصيدلي إذا كانت لديك أية أسئلة إضافية فيما يتعلق بتناول هذا الدواء.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل كافة الأدوية، فإن هذا الدواء يمكن أن يتسبب في ظهور بعض الأعراض جانبية، وعلى الرغم من ذلك فإنها لا تظهر على جميع المرضى.</p><p dir="RTL">يجب عليك التواصل فورا مع الطبيب إذا لاحظت أي من هذه الأعراض التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ بخدر أو ضعف في الذراع أو الساق أو الوجه، خاصة إن كان ذلك على جانب واحد من الجسم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ بالتشوش وصعوبة التحدث وفهم الآخرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصعوبة المفاجئة في المشي أو فقدان الاتزان أو التناسق الحركي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور المفاجئ بالدوار أو الصداع الشديد مع عدم معرفة السبب.</p><p dir="RTL">تُعدّ جميع الأعراض السابق ذكرها بالأعلى علامات للإصابة بجلطة دماغية. يعتبر الإصابة بجلطة دماغية أمر بعيد الحدوث في المرضى الذين لم يسبق لهم الإصابة بجلطة دماغية أو نوبة إقفارية عابرة ممن يتناولون هذا الدواء.</p><p dir="RTL">كما يجب عليك أيضا التواصل الفوري مع الطبيب إذا لاحظت أي من هذه الأعراض التالية:</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ارتفاع في درجة الحرارة وظهور كدمات تحت الجلد، قد تبدو مثل نقاط صغيرة حمراء، مع أو بدون تعب شديد غير مبرر، بالإضافة إلى الشعور بالتشوش مع اصفرار الجلد أو العينين (يرقان). (انظر الفقرة الثانية &quot;المعلومات التي يجب معرفتها قبل تناول بيڤاس&quot;).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>ظهور أي رد فعل تحسّسِي والذي يظهر في صورة طفح جلدي وشعور بالحكّة وتورم الوجه مع تورم الشفاه / اللسان أو قصر في النفس. (انظر الفقرة الثانية &quot;المعلومات التي يجب معرفتها قبل تناول بيڤاس&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">أخبر طبيبك فور ملاحظة أي من هذه الأعراض:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وجود دم في البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من فتحة الشرج، وجود دم في البراز أو تغير لون البراز إلى اللون الأسود.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف لا يمكن التحكم في إيقافه، على سبيل المثال: النزيف الناتج من جرح بسيط.</p><p dir="RTL">تعدّ جميع هذه الأعراض المذكورة بالأعلى من مؤشرات وجود النزيف الذي هو أشهر الأعراض الجانبية لهذا الدواء. وبرغم أنه من غير المألوف أن يتسبب هذا الدواء في النزيف الشديد، لكن حصول ذلك قد يهدد الحياة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية المألوفة (تؤثر في أقل من 1 إلى 10 أشخاص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف في المعدة أو الأمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من مكان حقن الإبرة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف من الأنف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كدمات حمراء صغيرة على الجلد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البول.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم دموي (نزيف تحت الجلد عند موضع الحقن في الجلد أو العضلات، مما يتسبب في حدوث تورم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص الهيموغلوبين أو نقص في عدد كريات الدم الحمراء (فقر دم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سهولة تكون الكدمات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية غير المألوفة (تؤثر في أقل من 1 إلى 100 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; رد فعل تحسسي / حساسية (تظهر في صورة الطفح الجلدي وشعور بالحكّة وتورم الوجه مع تورم الشفاه / اللسان أو قصر في النفس).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نزيف تلقائي من العين أو الشرج أو اللثة أو في البطن حول الأعضاء الداخلية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النزيف بعد العمليات الجراحية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سُعال دموي.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; دم في البراز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الأعراض الجانبية النادرة (تؤثر في أقل من 1 إلى 1000 شخص):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في عدد الصفائح الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ورم دموي تحت الجلد (نزيف تحت الجلد مما ينتج عنه تورم).</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يُحفظ الدواء بعيدا عن متناول الأطفال.</p><p dir="RTL">لا تستخدم الدواء بعد مرور تاريخ انتهاء الصلاحية الموضحة على شريط الأقراص وعلى العبوة بعد كلمة EXP.</p><p dir="RTL">&nbsp;يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير في الشهر.</p><p dir="RTL">لا تحفظ الدواء &nbsp;في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">يحفظ الدواء في علبته الأصلية من أجل الحفاظ عليه من الهواء والرطوبة.</p><p dir="RTL">لا تقم بإلقاء أي أدوية في مياه الصرف أو في النفايات المنزلية، وبدلاً عن ذلك قم باستشارة الصيدلي عن كيفية التخلص الآمن من الأدوية التي لم تعد في حاجة إليها. ستساعد هذه الإجراءات في المحافظة على البيئة.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>المادة الفعالة</u>: براسوجريل.</p><p dir="RTL">يحتوي كل قرص من دواء <strong>بيڤاس </strong><strong>5</strong><strong> ملغم </strong>على: 5 ملغم من المادة الفعالة براسوجريل (في صورة هيدروكلورايد).</p><p dir="RTL">يحتوي كل قرص من دواء <strong>بيڤاس 10 ملغم </strong>على: 10 ملغم من المادة الفعالة براسوجريل (في صورة هيدروكلورايد).</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <u>باقي المكونات</u>:</p><p dir="RTL">سليلوز دقيق البلورات، رشات المانيتول المجففة، وكروس كارميلوز الصوديوم، وهيدروكسيبروبايل ميثايل سيليلوز&nbsp; 5سيبي ، واستيارات الماغنيسيوم، أوبادري الأبيض OYL 28900، وأكسيد الحديد الأصفر، ( وأكسيد الحديد الأحمر ل <strong>بيڤاس10 ملغم)</strong> .</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>بيڤاس </strong><strong>5</strong><strong> ملغم: </strong>&nbsp;أقراص مسطحة صفراء اللون ، منقوش عليها &quot;U33&quot; من جانب &nbsp;ومنبسطة من الجانب الآخر.</p><p dir="RTL">بيڤاس 10 ملغم:&nbsp; أقراص محدبة على كلا الجانبين ذات غطاء رأس بيج ، منقوشة بـ &quot;T10&quot; من جانب ومنبسطة من الجانب الآخر.</p><p dir="RTL"><strong>&nbsp;</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">إم إس فارما السعودية،</p><p dir="RTL">الرياض ، المملكة العربية السعودية .</p><p dir="RTL">&nbsp;info-ksa@mspharma.com</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>صنعت بواسطة </strong><strong>:</strong></p><p dir="RTL">المتحدة للصناعات الدوائية &nbsp;&ndash; الأردن <strong>لصالح </strong>إم إس فارما &ndash; المملكة العربية السعودية</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            Feb-2020
SPM190357

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pevas 10 mg film-coated tablets.
Pevas 5 mg film-coated tablets.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Pevas 10 mg:
Each tablet contains 10 mg prasugrel (as hydrochloride).
Pevas 5 mg:
Each tablet contains 5 mg prasugrel (as hydrochloride).
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet (tablet).
Pevas 10 mg:
Beige caplet biconvex shape tablets, embossed with “T10” from one side and plain from other side.
Pevas 5 mg:
Yellow caplet flat tablets, embossed with “U33” from one side and plain from other side.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pevas, co-administered with acetylsalicylic acid (ASA), is indicated for the prevention of atherothrombotic events in adult patients with acute coronary syndrome (i.e. unstable angina, non-ST segment elevation myocardial infarction [UA/NSTEMI] or ST segment elevation myocardial infarction [STEMI]) undergoing primary or delayed percutaneous coronary intervention (PCI).</p><p>For further information please refer to section 5.1.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>Adults</p><p>Pevas should be initiated with a single 60 mg loading dose and then continued at 10 mg once a day. In UA/NSTEMI patients, where coronary angiography is performed within 48 hours after admission, the loading dose should only be given at the time of PCI (see sections 4.4, 4.8 and 5.1). Patients taking Pevas should also take ASA daily (75 mg to 325 mg).</p><p>&nbsp;</p><p>In patients with acute coronary syndrome (ACS) who are managed with PCI, premature discontinuation of any antiplatelet agent, including Pevas, could result in an increased risk of thrombosis, myocardial infarction or death due to the patient&#39;s underlying disease. A treatment of up to 12 months is recommended unless the discontinuation of Pevas is clinically indicated (see sections&nbsp;4.4 and 5.1).</p><p>&nbsp;</p><p>Patients&nbsp;&ge;&nbsp;75 years old</p><p>The use of Pevas in patients &ge; 75 years of age is generally not recommended. If, after a careful individual benefit/risk evaluation by the prescribing physician (see section 4.4), treatment is deemed necessary in the patients age group &ge; 75 years, then following a 60 mg loading dose a reduced maintenance dose of 5 mg should be prescribed. Patients &ge; 75 years of age have greater sensitivity to bleeding and higher exposure to the active metabolite of prasugrel (see sections 4.4, 4.8, 5.1 and 5.2).</p><p>&nbsp;</p><p>Patients weighing &lt; 60 kg</p><p>Pevas should be given as a single 60 mg loading dose and then continued at a 5 mg once daily dose. The 10 mg maintenance dose is not recommended. This is due to an increase in exposure to the active metabolite of prasugrel, and an increased risk of bleeding in patients with body weight &lt; 60 kg when given a 10 mg once daily dose compared with patients &ge; 60 kg (see sections 4.4, 4.8 and 5.2).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Renal impairment</u></p><p>No dose adjustment is necessary for patients with renal impairment, including patients with end stage renal disease (see section 5.2). There is limited therapeutic experience in patients with renal impairment (see section 4.4).</p><p><u>Hepatic impairment</u></p><p>No dose adjustment is necessary in subjects with mild to moderate hepatic impairment (Child Pugh class A and B) (see section 5.2). There is limited therapeutic experience in patients with mild and moderate hepatic dysfunction (see section 4.4). Pevas is contraindicated in patients with severe hepatic impairment (Child Pugh class C).</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Pevas in children below age 18 has not been established. Limited data are available in children with sickle cell anaemia (see section 5.1).</p><p><u>Method of administration</u></p><p>For oral use. Pevas may be administered with or without food. Administration of the 60 mg prasugrel loading dose in the fasted state may provide most rapid onset of action (see section 5.2). Do not crush or break the tablet.</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.

Active pathological bleeding.

History of stroke or transient ischaemic attack (TIA).

Severe hepatic impairment (Child Pugh class C).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Bleeding risk</u></p><p>In the phase 3 clinical trial (TRITON) key exclusion criteria included an increased risk of bleeding; anaemia; thrombocytopenia; a history of pathological intracranial findings. Patients with acute coronary syndromes undergoing PCI treated with Pevas and ASA showed an increased risk of major and minor bleeding according to the TIMI classification system. Therefore, the use of Pevas in patients at increased risk of bleeding should only be considered when the benefits in terms of prevention of ischaemic events are deemed to outweigh the risk of serious bleedings. This concern applies especially to patients:</p><p>&bull; &ge; 75 years of age (see below).</p><p>&bull; with a propensity to bleed (e.g. due to recent trauma, recent surgery, recent or recurrent gastrointestinal bleeding, or active peptic ulcer disease)</p><p>&bull; with body weight &lt; 60 kg (see sections 4.2 and 4.8). In these patients the 10 mg maintenance dose is not recommended. A 5 mg maintenance dose should be used.</p><p>&bull; with concomitant administration of medicinal products that may increase the risk of bleeding, including oral anticoagulants, clopidogrel, non-steroidal anti-inflammatory drugs (NSAIDs), and fibrinolytic.</p><p>For patients with active bleeding for whom reversal of the pharmacological effects of Pevas is required, platelet transfusion may be appropriate.</p><p>&nbsp;</p><p>The use of Pevas in patients &ge;75 years of age is generally not recommended and should only be undertaken with caution after a careful individual benefit/risk evaluation by the prescribing physician indicates that benefits in terms of prevention of ischaemic events outweigh the risk of serious bleedings. In the phase 3 clinical trial these patients were at greater risk of bleeding, including fatal bleeding, compared to patients &lt;75 years of age. If prescribed, a lower maintenance dose of 5 mg should be used; the 10 mg maintenance dose is not recommended (see sections 4.2 and 4.8).</p><p>&nbsp;</p><p>Therapeutic experience with prasugrel is limited in patients with renal impairment (including ESRD) and in patients with moderate hepatic impairment. These patients may have an increased bleeding risk. Therefore, prasugrel should be used with caution in these patients.</p><p>Patients should be told that it might take longer than usual to stop bleeding when they take prasugrel (in combination with ASA), and that they should report any unusual bleeding (site or duration) to their physician.</p><p>&nbsp;</p><p>Bleeding Risk Associated with Timing of Loading Dose in NSTEMI.</p><p>In a clinical trial of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, a prasugrel loading dose given on average 4 hours prior to coronary angiography increased the risk of major and minor peri-procedural bleeding compared with a prasugrel loading dose at the time of PCI. Therefore, in UA/NSTEMI patients, where coronary angiography is performed within 48 hours after admission, the loading dose should be given at the time of PCI. (see sections 4.2, 4.8 and 5.1).</p><p>&nbsp;</p><p><u>Surgery</u></p><p>Patients should be advised to inform physicians and dentists that they are taking prasugrel before any surgery is scheduled and before any new medicinal product is taken. If a patient is to undergo elective surgery, and an antiplatelet effect is not desired, Pevas should be discontinued at least 7 days prior to surgery. Increased frequency (3-fold) and severity of bleeding may occur in patients undergoing CABG surgery within 7 days of discontinuation of prasugrel (see section 4.8).</p><p>The benefits and risks of prasugrel should be carefully considered in patients in whom the coronary anatomy has not been defined and urgent CABG is a possibility.</p><p>&nbsp;</p><p><u>Hypersensitivity including angioedema</u></p><p>Hypersensitivity reactions including angioedema have been reported in patients receiving prasugrel, including in patients with a history of hypersensitivity reaction to clopidogrel. Monitoring for signs of hypersensitivity in patients with a known allergy to thienopyridines is advised (see section 4.8).</p><p>&nbsp;</p><p><u>Thrombotic Thrombocytopaenic Purpura (TTP)</u></p><p>TTP has been reported with the use of prasugrel. TTP is a serious condition and requires prompt treatment.</p><p>&nbsp;</p><p><u>Morphine and other opioids</u></p><p>Reduced prasugrel efficacy has been seen in patients co-administered prasugrel and morphine (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Warfarin:</p><p>Concomitant administration of Pevas with coumarin derivatives other than warfarin has not been studied. Because of the potential for increased risk of bleeding, warfarin (or other coumarin derivatives) and prasugrel should be co-administered with caution (see section 4.4).</p><p>Non-steroidal anti-inflammatory drugs (NSAIDs):</p><p>Concomitant administration with chronic NSAIDs has not been studied. Because of the potential for increased risk of bleeding, chronic NSAIDs (including COX-2 inhibitors) and Pevas should be co-administered with caution (see section 4.4).</p><p>&nbsp;</p><p>Pevas can be concomitantly administered with medicinal products metabolized by cytochrome P450 enzymes (including statins), or medicinal products that are inducers or inhibitors of cytochrome P450 enzymes. Pevas can also be concomitantly administered with ASA, heparin, digoxin, and medicinal products that elevate gastric pH, including proton pump inhibitors and H<sub>2</sub>&nbsp;blockers. Although not studied in specific interaction studies, Pevas has been co-administered in the phase 3 clinical trial with low molecular weight heparin, bivalirudin, and GP IIb/IIIa inhibitors (no information available regarding the type of GP IIb/IIIa inhibitor used) without evidence of clinically significant adverse interactions.</p><p>&nbsp;</p><p><u>Effects of other medicinal products on </u>Pevas</p><p><u>Acetylsalicylic acid:</u></p><p>Pevas is to be administered concomitantly with acetylsalicylic acid (ASA). Although a pharmacodynamic interaction with ASA leading to an increased risk of bleeding is possible, the demonstration of the efficacy and safety of prasugrel comes from patients concomitantly treated with ASA.</p><p><u>Heparin:</u></p><p>A single intravenous bolus dose of unfractionated heparin (100 U/kg) did not significantly alter the prasugrel-mediated inhibition of platelet aggregation. Likewise, prasugrel did not significantly alter the effect of heparin on measures of coagulation. Therefore, both medicinal products can be administered concomitantly.<strong>&nbsp;</strong>An increased risk of bleeding is possible when Pevas is co-administered with heparin.</p><p><u>Statins:</u></p><p>Atorvastatin (80 mg daily) did not alter the pharmacokinetics of prasugrel and its inhibition of platelet aggregation. Therefore, statins that are substrates of CYP3A are not anticipated to have an effect on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.</p><p>Medicinal products that elevate gastric pH:</p><p>Daily co-administration of ranitidine (an H<sub>2&nbsp;</sub>blocker) or lansoprazole (a proton pump inhibitor) did not change the prasugrel active metabolite&#39;s AUC and T<sub>max</sub>, but decreased the C<sub>max&nbsp;</sub>by 14% and 29%, respectively. In the phase 3 clinical trial, Pevas was administered without regard to co-administration of a proton pump inhibitor or H<sub>2</sub>&nbsp;blocker. Administration of the 60 mg prasugrel loading dose without concomitant use of proton pump inhibitors may provide most rapid onset of action.</p><p><u>Inhibitors of CYP3A:</u></p><p>Ketoconazole (400 mg daily), a selective and potent inhibitor of CYP3A4 and CYP3A5, did not affect prasugrel-mediated inhibition of platelet aggregation or the prasugrel active metabolite&#39;s AUC and T<sub>max</sub>, but decreased the C<sub>max</sub>&nbsp;by 34% to 46%. Therefore, CYP3A inhibitors such as azol antifungals, HIV protease inhibitors, clarithromycin, telithromycin, verapamil, diltiazem, indinavir, ciprofloxacin, and grapefruit juice are not anticipated to have a significant effect on the pharmacokinetics of the active metabolite.</p><p><u>Inducers of cytochromes P450:</u></p><p>Rifampicin (600 mg daily), a potent inducer of CYP3A and CYP2B6, and an inducer of CYP2C9, CYP2C19, and CYP2C8, did not significantly change the pharmacokinetics of prasugrel. Therefore, known CYP3A inducers such as rifampicin, carbamazepine, and other inducers of cytochromes P450 are not anticipated to have significant effect on the pharmacokinetics of the active metabolite.</p><p><u>Morphine and other opioids:</u></p><p>A delayed and decreased exposure to oral P2Y12 inhibitors, including prasugrel and its active metabolite, has been observed in patients with acute coronary syndrome treated with morphine. This interaction may be related to reduced gastrointestinal motility and apply to other opioids. The clinical relevance is unknown, but data indicate the potential for reduced prasugrel efficacy in patients co-administered prasugrel and morphine. In patients with acute coronary syndrome, in whom morphine cannot be withheld and fast P2Y12 inhibition is deemed crucial, the use of a parenteral P2Y12 inhibitor may be considered.</p><p><u>Effects of Pevas on other medicinal products</u></p><p><u>Digoxin:</u></p><p>Prasugrel has no clinically significant effect on the pharmacokinetics of digoxin.</p><p>Medicinal products metabolized by CYP2C9:</p><p>Prasugrel did not inhibit CYP2C9, as it did not affect the pharmacokinetics of S-warfarin. Because of the potential for increased risk of bleeding, warfarin and Pevas should be co-administered with caution (see section 4.4).</p><p><u>Medicinal products metabolized by CYP2B6:</u></p><p>Prasugrel is a weak inhibitor of CYP2B6. In healthy subjects, prasugrel decreased exposure to hydroxybupropion, a CYP2B6-mediated metabolite of bupropion, by 23%. This effect is likely to be of clinical concern only when prasugrel is co-administered with medicinal products for which CYP2B6 is the only metabolic pathway and have a narrow therapeutic window (e.g. cyclophosphamide, efavirenz).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No clinical study has been conducted in pregnant or breast-feeding women.</p><p><u>Pregnancy</u></p><p>Animal studies do not indicate direct harmful effects with respect to pregnancy, embryonal/foetal development, parturition or postnatal development (see section 5.3). Because animal reproduction studies are not always predictive of a human response, Pevas should be used during pregnancy only if the potential benefit to the mother justifies the potential risk to the fetus.</p><p><u>Breast-feeding</u></p><p>It is unknown whether prasugrel is excreted in human breast milk. Animal studies have shown excretion of prasugrel in breast milk. The use of prasugrel during breastfeeding is not recommended.</p><p><u>Fertility</u></p><p>Prasugrel had no effect on fertility of male and female rats at oral doses up to an exposure 240 times the recommended daily human maintenance dose (based on mg/m<sup>2</sup>).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prasugrel is expected to have no or negligible influence on the ability to drive and use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Summary of the safety profile</strong></p><p>Safety in patients with acute coronary syndrome undergoing PCI was evaluated in one clopidogrel-controlled study (TRITON) in which 6741 patients were treated with prasugrel (60 mg loading dose and 10 mg once daily maintenance dose) for a median of 14.5 months (5802 patients were treated for over 6 months, 4136 patients were treated for more than 1 year). The rate of study drug discontinuation due to adverse events was 7.2% for prasugrel and 6.3% for clopidogrel. Of these, bleeding was the most common adverse reaction for both drugs leading to study drug discontinuation (2.5% for prasugrel and 1.4% for clopidogrel).</p><p><u>Bleeding</u></p><p>Non-Coronary Artery Bypass Graft (CABG) related bleeding</p><p>In TRITON, the frequency of patients experiencing a non-CABG related bleeding event is shown in Table 1. The incidence of Non-CABG-related TIMI major bleeding, including life-threatening and fatal, as well as TIMI minor bleeding, was statistically significantly higher in subjects treated with prasugrel compared to clopidogrel in the UA/NSTEMI and All ACS populations. No significant difference was seen in the STEMI population. The most common site of spontaneous bleeding was the gastrointestinal tract (1.7% rate with prasugrel and 1.3% rate with clopidogrel); the most frequent site of provoked bleeding was the arterial puncture site (1.3% rate with prasugrel and 1.2% with clopidogrel).</p><p>&nbsp;</p><p><strong>Table 1: Incidence of Non-CABG related bleeding<sup>a</sup>&nbsp;(% Patients)</strong></p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:629px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>Event</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>All ACS</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>UA/NSTEMI</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>STEMI</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Prasugrel<sup>b</sup>+ASA</strong></p><p><strong>(N = 6741)</strong></p></td><td style="vertical-align:top"><p><strong>Clopidogrel<sup>b</sup>+ASA</strong></p><p><strong>(N = 6716)</strong></p></td><td style="vertical-align:top"><p><strong>Prasugrel<sup>b</sup>+ASA</strong></p><p><strong>(N = 5001)</strong></p></td><td style="vertical-align:top"><p><strong>Clopidogrel<sup>b</sup>+ASA</strong></p><p><strong>(N = 4980)</strong></p></td><td style="vertical-align:top"><p><strong>Prasugrel<sup>b</sup>+ASA</strong></p><p><strong>(N = 1740)</strong></p></td><td style="vertical-align:top"><p><strong>Clopidogrel<sup>b</sup>+ASA</strong></p><p><strong>(N = 1736)</strong></p></td></tr><tr><td style="vertical-align:top"><p>TIMI major bleeding<sup>c</sup></p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>2.0</p></td></tr><tr><td style="vertical-align:top"><p>Life-threatening<sup>d</sup></p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.0</p></td></tr><tr><td style="vertical-align:top"><p>Fatal</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic ICH<sup>e</sup></p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.2</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Requiring inotropes</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Requiring surgical intervention</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Requiring transfusion (&ge; 4 units)</p></td><td style="vertical-align:top"><p>0.7</p></td><td style="vertical-align:top"><p>0.5</p></td><td style="vertical-align:top"><p>0.6</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.8</p></td></tr><tr><td style="vertical-align:top"><p>TIMI minor bleeding&nbsp;<sup>f</sup></p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>1.9</p></td><td style="vertical-align:top"><p>2.3</p></td><td style="vertical-align:top"><p>1.6</p></td><td style="vertical-align:top"><p>2.7</p></td><td style="vertical-align:top"><p>2.6</p></td></tr></tbody></table><p>a Centrally adjudicated events defined by the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria.</p><p>b Other standard therapies were used as appropriate.</p><p>c Any intracranial hemorrhage or any clinically overt bleeding associated with a fall in hemoglobin &ge;5 g/dL.</p><p>d Life-threatening bleeding is a subset of TIMI major bleeding and includes the types indented below. Patients may be counted in more than one row.</p><p>e ICH=intracranial hemorrhage.</p><p>f Clinically overt bleeding associated with a fall in hemoglobin of &ge;3 g/dL but &lt;5 g/dL.</p><p><u>Patients&nbsp;</u>&ge;<u>&nbsp;75 years old</u></p><p>Non-CABG-related TIMI major or minor bleeding rates:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Age</p></td><td style="vertical-align:top"><p>Prasugrel&nbsp;<strong>10</strong>&nbsp;<strong>mg</strong></p></td><td style="vertical-align:top"><p>Clopidogrel 75 mg</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;</strong>75 years (N=1785)*</p></td><td style="vertical-align:top"><p>9.0% (1.0% fatal)</p></td><td style="vertical-align:top"><p>6.9% (0.1% fatal)</p></td></tr><tr><td style="vertical-align:top"><p>&lt;75 years (N=11672)*</p></td><td style="vertical-align:top"><p>3.8% (0.2% fatal)</p></td><td style="vertical-align:top"><p>2.9% (0.1% fatal)</p></td></tr><tr><td style="vertical-align:top"><p>&lt;75 years (N=7180)**</p></td><td style="vertical-align:top"><p>2.0% (0.1% fatal)&nbsp;<sup>a</sup></p></td><td style="vertical-align:top"><p>1.3% (0.1% fatal)</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Prasugrel&nbsp;<strong>5 mg</strong></p></td><td style="vertical-align:top"><p>Clopidogrel 75 mg</p></td></tr><tr><td style="vertical-align:top"><p>&ge;75 years (N=2060)**</p></td><td style="vertical-align:top"><p>2.6% (0.3% fatal)</p></td><td style="vertical-align:top"><p>3.0% (0.5% fatal)</p></td></tr></tbody></table><p>*TRITON study in ACS patients undergoing PCI</p><p>**TRILOGY-ACS study in patients not undergoing PCI (see 5.1):</p><p><sup>a</sup>&nbsp;10 mg prasugrel; 5 mg prasugrel if &lt;60 kg</p><p><u>Patients &lt; 60 kg</u></p><p>Non-CABG-related TIMI major or minor bleeding rates:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>Weight</p></td><td style="vertical-align:top"><p>Prasugrel&nbsp;<strong>10</strong>&nbsp;<strong>mg</strong></p></td><td style="vertical-align:top"><p>Clopidogrel 75 mg</p></td></tr><tr><td style="vertical-align:top"><p>&lt;60 kg (N=664)*</p></td><td style="vertical-align:top"><p>10.1% (0% fatal)</p></td><td style="vertical-align:top"><p>6.5% (0.3% fatal)</p></td></tr><tr><td style="vertical-align:top"><p><strong>&ge;</strong>60 kg (N=12672)*</p></td><td style="vertical-align:top"><p>4.2% (0.3% fatal)</p></td><td style="vertical-align:top"><p>3.3% (0.1% fatal)</p></td></tr><tr><td style="vertical-align:top"><p>&ge;60 kg (N=7845)**</p></td><td style="vertical-align:top"><p>2.2% (0.2% fatal)&nbsp;<sup>a</sup></p></td><td style="vertical-align:top"><p>1.6% (0.2% fatal)</p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Prasugrel&nbsp;<strong>5 mg</strong></p></td><td style="vertical-align:top"><p>Clopidogrel 75 mg</p></td></tr><tr><td style="vertical-align:top"><p>&lt;60kg (N=1391)**</p></td><td style="vertical-align:top"><p>1.4% (0.1% fatal)</p></td><td style="vertical-align:top"><p>2.2% (0.3% fatal)</p></td></tr></tbody></table><p>*TRITON study in ACS patients undergoing PCI</p><p>**TRILOGY-ACS study in patients not undergoing PCI (see 5.1):</p><p><sup>a</sup>&nbsp;10 mg prasugrel; 5 mg prasugrel if &ge;75 years of age</p><p><u>Patients &ge;60 kg and age &lt;75 years</u></p><p>In patients &ge;60 kg&nbsp;and&nbsp;age &lt;75 years, non-CABG-related TIMI major or minor bleeding rates were 3.6% for prasugrel and 2.8% for clopidogrel; rates for fatal bleeding were 0.2% for prasugrel and 0.1% for clopidogrel.</p><p><u>CABG-related bleeding</u></p><p>In the phase 3 clinical trial, 437 patients underwent CABG during the course of the study. Of those patients, the rate of CABG-related TIMI major or minor bleeding was 14.1% for the prasugrel group and 4.5% in the clopidogrel group. The higher risk for bleeding events in subjects treated with prasugrel persisted up to 7 days from the most recent dose of study drug. For patients who received their thienopyridine within 3 days prior to CABG, the frequencies of TIMI major or minor bleeding were 26.7% (12 of 45 patients) in the prasugrel group, compared with 5.0% (3 of 60 patients) in the clopidogrel group. For patients who received their last dose of thienopyridine within 4 to 7 days prior to CABG, the frequencies decreased to 11.3% (9 of 80 patients) in the prasugrel group and 3.4% (3 of 89 patients) in the clopidogrel group. Beyond 7 days after drug discontinuation, the observed rates of CABG-related bleeding were similar between treatment groups (see section 4.4).</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Bleeding Risk Associated with Timing of Loading Dose in NSTEMI</u></p><p>In a clinical study of NSTEMI patients (the ACCOAST study), where patients were scheduled to undergo coronary angiography within 2 to 48 hours after randomization, patients given a 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of PCI had an increased risk of non-CABG peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of PCI (see sections 4.2 and 4.4). Non-CABG- related TIMI bleeding rates through 7 days for patients were as follows:</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>Adverse Reaction</strong></p></td><td style="vertical-align:top"><p><strong>Prasugrel Prior to Coronary Angiography<sup>a</sup></strong></p><p><strong>(N=2037)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>Prasugrel At time of PCI<sup>a</sup></strong></p><p><strong>(N=1996)</strong></p><p><strong>%</strong></p></td></tr><tr><td style="vertical-align:top"><p>TIMI Major bleeding<sup>b</sup></p></td><td style="vertical-align:top"><p>1.3</p></td><td style="vertical-align:top"><p>0.5</p></td></tr><tr><td style="vertical-align:top"><p>Life-threatening<sup>c</sup></p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Fatal</p></td><td style="vertical-align:top"><p>0.1</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Symptomatic ICH<sup>d</sup></p></td><td style="vertical-align:top"><p>0.0</p></td><td style="vertical-align:top"><p>0.0</p></td></tr><tr><td style="vertical-align:top"><p>Requiring inotropes</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.2</p></td></tr><tr><td style="vertical-align:top"><p>Requiring surgical intervention</p></td><td style="vertical-align:top"><p>0.4</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>Requiring transfusion (&ge;4 units)</p></td><td style="vertical-align:top"><p>0.3</p></td><td style="vertical-align:top"><p>0.1</p></td></tr><tr><td style="vertical-align:top"><p>TIMI Minor bleeding<sup>e</sup></p></td><td style="vertical-align:top"><p>1.7</p></td><td style="vertical-align:top"><p>0.6</p></td></tr></tbody></table><p><sup>a</sup>Other standard therapies were used as appropriate. The clinical study protocol provided for all patients to receive aspirin and a daily maintenance dose of prasugrel.</p><p><sup>b</sup>Any intracranial haemorrhage or any clinically overt bleeding associated with a fall in haemoglobin &ge;5 g/dL.</p><p><sup>c</sup>Life-threatening is a subset of TIMI Major bleeding and includes the types indented below. Patients may be counted in more than one row.</p><p><sup>d</sup>ICH=intracranial haemorrhage.</p><p><sup>e</sup>Clinically overt bleeding associated with a fall in haemoglobin of &ge;3 g/dL but &lt;5 g/dL.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Tabulated summary of adverse reactions</strong></p><p>Table 2 summarises haemorrhagic and non-haemorrhagic adverse reactions in TRITON, or that were spontaneously reported, classified by frequency and system organ class. Frequencies are defined as follows:</p><p>Very common (&ge; 1/10); common (&ge; 1/100 to &lt; 1/10); uncommon (&ge; 1/1000 to &lt; 1/100);</p><p>rare (&ge; 1/10,000 to &lt;1/1,000); very rare (&lt; 1/10,000); not known (cannot be estimated from the available data).</p><p><strong>Table 2</strong>:&nbsp;<strong>Haemorrhagic and</strong>&nbsp;<strong>Non-haemorrhagic adverse reactions</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p><strong>System Organ Class</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td><td style="vertical-align:top"><p><strong>Not Known</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and Lymphatic System disorders</p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopaenia</p></td><td style="vertical-align:top"><p>Thrombotic thrombocytopaenic purpura (TTP)&nbsp;-see section 4.4</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hypersensitivity including angioedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Eye haemorrhage</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Vascular Disorders</p></td><td style="vertical-align:top"><p>Haematoma</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Epistaxis</p></td><td style="vertical-align:top"><p>Haemoptysis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Gastrointestinal haemorrhage</p></td><td style="vertical-align:top"><p>Retroperitoneal haemorrhage</p><p>Rectal haemorrhage</p><p>Haematochezia</p><p>Gingival bleeding</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p><p>Ecchymosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Vessel puncture site haematoma</p><p>Puncture site haemorrhage</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Injury, poisoning and procedural complications</p></td><td style="vertical-align:top"><p>Contusion</p></td><td style="vertical-align:top"><p>Post-procedural haemorrhage</p></td><td style="vertical-align:top"><p>Subcutaneous haematoma</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>In patients with or without a history of TIA or stroke, the incidence of stroke in the phase 3 clinical trial was as follows (see section 4.4):</p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:top"><p>History of TIA or stroke</p></td><td style="vertical-align:top"><p>Prasugrel</p></td><td style="vertical-align:top"><p>Clopidogrel</p></td></tr><tr><td style="vertical-align:top"><p>Yes (N=518)</p></td><td style="vertical-align:top"><p>6.5% (2.3% ICH*)</p></td><td style="vertical-align:top"><p>1.2% (0% ICH*)</p></td></tr><tr><td style="vertical-align:top"><p>No (N=13090)</p></td><td style="vertical-align:top"><p>0.9% (0.2% ICH*)</p></td><td style="vertical-align:top"><p>1.0% (0.3% ICH*)</p></td></tr></tbody></table><p>* ICH=intracranial haemorrhage.</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Overdose of Pevas may lead to prolonged bleeding time and subsequent bleeding complications. No data are available on the reversal of the pharmacological effect of prasugrel; however, if prompt correction of prolonged bleeding time is required, platelet transfusion and/or other blood products may be considered.</p><p>&nbsp;</p><p><strong>To reports any side effect(s):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><p dir="RTL"><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_2" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:.6pt;margin-top:6.55pt;width:375.05pt;height:93pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:3.6pt;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:3.6pt;
 mso-position-horizontal:absolute;mso-position-horizontal-relative:text;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='mso-layout-grid-align:none;text-autospace:
    none'><span dir=LTR style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>- The National Pharmacovigilance
    and Drug Safety Centre (NPC) :<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Fax:
    +966-11-205-7662<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Call NPC
    at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Toll free
    phone: 8002490000<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"TimesNewRomanPSMT",serif;
    mso-bidi-font-family:TimesNewRomanPSMT'>npc.drug@sfda.gov.sa</span></a><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt;mso-list:
    l2 level1 lfo1;mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "Times New Roman",serif'>Website: www.sfda.gov.sa/npc</span><span
    style='font-family:"TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt;mso-list:l2 level1 lfo1;
    mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
    style='font-family:Symbol;mso-fareast-font-family:Symbol;mso-bidi-font-family:
    Symbol'><span style='mso-list:Ignore'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-family:
    "TimesNewRomanPSMT",serif;mso-bidi-font-family:TimesNewRomanPSMT'>Website:
    www.sfda.gov.sa/npc<o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-indent:-18.0pt'><span dir=LTR><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap type="square"/>
</v:shape><![endif]--><img width="506" height="130" alt="Text Box: - The National Pharmacovigilance and Drug Safety Centre (NPC) :
•	Fax: +966-11-205-7662
•	Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.
•	Toll free phone: 8002490000
•	E-mail: npc.drug@sfda.gov.sa
•	Website: www.sfda.gov.sa/npc
•	Website: www.sfda.gov.sa/npc

" src="file:///C:/Users/ABDUAL~1/AppData/Local/Temp/msohtmlclip1/01/clip_image001.gif" /></p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p><strong>&nbsp;</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>5.1 Pharmacodynamic properties</strong></p><p>Pharmacotherapeutic group: Platelet aggregation inhibitors excluding heparin, ATC code: B01AC22.</p><p><u>Mechanism of action / Pharmacodynamic effects</u></p><p>Prasugrel is an inhibitor of platelet activation and aggregation through the irreversible binding of its active metabolite to the P2Y<sub>12&nbsp;</sub>class of ADP receptors on platelets. Since platelets participate in the initiation and/or evolution of thrombotic complications of atherosclerotic disease, inhibition of platelet function can result in the reduction of the rate of cardiovascular events such as death, myocardial infarction, or stroke.</p><p>&nbsp;</p><p>Following a 60 mg loading dose of prasugrel, inhibition of ADP-induced platelet aggregation occurs at 15 minutes with 5 &micro;M ADP and 30 minutes with 20 &micro;M ADP. The maximum inhibition by prasugrel of ADP-induced platelet aggregation is 83% with 5 &micro;M ADP and 79% with 20 &micro;M ADP, in both cases with 89% of healthy subjects and patients with stable atherosclerosis achieving at least 50% inhibition of platelet aggregation by 1 hour. Prasugrel-mediated inhibition of platelet aggregation exhibits low between-subject (9%) and within-subject (12%) variability with both 5 &micro;M and 20 &micro;M ADP. Mean steady-state inhibition of platelet aggregation was 74% and 69% respectively for 5 &micro;M ADP and 20 &micro;M ADP, and was achieved following 3 to 5 days of administration of the 10 mg prasugrel maintenance dose preceded by a 60 mg loading dose. More than 98% of subjects had &ge; 20% inhibition of platelet aggregation during maintenance dosing.</p><p>&nbsp;</p><p>Platelet aggregation gradually returned to baseline values after treatment in 7 to 9 days after administration of a single 60 mg loading dose of prasugrel and in 5 days following discontinuation of maintenance dosing at steady-state.</p><p>&nbsp;</p><p><u>Switching data</u>:&nbsp;Following administration of 75 mg clopidogrel once daily for 10 days, 40 healthy subjects were switched to prasugrel 10 mg once daily with or without a loading dose of 60 mg. Similar or higher inhibition of platelet aggregation was observed with prasugrel. Switching directly to prasugrel 60 mg loading dose resulted in the most rapid onset of higher platelet inhibition. Following administration of a 900 mg loading dose of clopidogrel (with ASA), 56 subjects with ACS were treated for 14 days with either prasugrel 10 mg once daily or clopidogrel 150 mg once daily, and then switched to either clopidogrel 150 mg or prasugrel 10 mg for another 14 days. Higher inhibition of platelet aggregation was observed in patients switched to prasugrel 10 mg compared with those treated with clopidogrel 150 mg. In a study of 276 ACS patients managed with PCI, switching from an initial loading dose of 600 mg clopidogrel or placebo administered upon presentation to the hospital prior to coronary angiography to a 60 mg loading dose of prasugrel administered at the time of percutaneous coronary intervention, resulted in a similar increased inhibition of platelet aggregation for the 72 hour duration of the study.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p><u>Acute Coronary Syndrome (ACS)</u></p><p>The phase 3 TRITON study compared Pevas (prasugrel) with clopidogrel, both co-administered with ASA and other standard therapy. TRITON was a 13,608 patient, multicentre international, randomised, double blind, parallel group study. Patients had ACS with moderate to high risk UA, NSTEMI, or STEMI and were managed with PCI.</p><p>&nbsp;</p><p>Patients with UA/NSTEMI within 72 hours of symptoms or STEMI between 12 hours to 14 days of symptoms were randomised after knowledge of coronary anatomy. Patients with STEMI within 12 hours of symptoms and planned for primary PCI could be randomised without knowledge of coronary anatomy. For all patients, the loading dose could be administered anytime between randomisation and 1 hour after the patient left the catheterisation lab.</p><p>Patients randomised to receive prasugrel (60 mg loading dose followed by 10 mg once daily) or clopidogrel (300 mg loading dose followed by 75 mg once daily) were treated for a median of 14.5 months (maximum of 15 months with a minimum of 6 months follow-up). Patients also received ASA (75 mg to 325 mg once daily). Use of any thienopyridine within 5 days before enrolment was an exclusion criterion. Other therapies, such as heparin and GPIIb/IIIa inhibitors, were administered at the discretion of the physician. Approximately 40% of patients (in each of the treatment groups) received GPIIb/IIIa inhibitors in support of PCI (no information available regarding the type of GP IIb/IIIa inhibitor used). Approximately 98% of patients (in each of the treatment groups) received antithrombins (heparin, low molecular weight heparin, bivalirudin, or other agent) directly in support of PCI.</p><p>&nbsp;</p><p>The trial&#39;s primary outcome measure was the time to first occurrence of cardiovascular (CV) death, non-fatal myocardial infarction (MI), or non-fatal stroke. Analysis of the composite endpoint in the All ACS population (combined UA/NSTEMI and STEMI cohorts) was contingent on showing statistical superiority of prasugrel versus clopidogrel in the UA/NSTEMI cohort (p &lt; 0.05).</p><p>&nbsp;</p><p><u>All ACS population</u>:</p><p>Pevas showed superior efficacy compared to clopidogrel in reducing the primary composite outcome events as well as the pre-specified secondary outcome events, including stent thrombosis (see Table 3). The benefit of prasugrel was apparent within the first 3 days and it persisted to the end of study. The superior efficacy was accompanied by an increase in major bleeding (see sections 4.4 and 4.8). The patient population was 92% Caucasian, 26% female, and 39% &ge; 65 years of age. The benefits associated with prasugrel were independent of the use of other acute and long-term cardiovascular therapies, including heparin/low molecular weight heparin, bivalirudin, intravenous GPIIb/IIIa inhibitors, lipid-lowering medicinal products, beta-blockers, and angiotensin converting enzyme inhibitors. The efficacy of prasugrel was independent of the ASA dose (75 mg to 325 mg once daily). The use of oral anticoagulants, non-study antiplatelet medicinal products and chronic NSAIDs was not allowed in TRITON. In the All ACS population, prasugrel was associated with a lower incidence of CV death, non-fatal MI, or non-fatal stroke compared to clopidogrel, regardless of baseline characteristics such as age, sex, body weight, geographical region, use of GPIIb/IIIa inhibitors, and stent type. The benefit was primarily due to a significant decrease in non-fatal MI (see Table 3). Subjects with diabetes had significant reductions in the primary and all secondary composite endpoints.</p><p>The observed benefit of prasugrel in patients &ge; 75 years was less than that observed in patients &lt; 75 years. Patients &ge; 75 years were at increased risk of bleeding, including fatal (see sections 4.2, 4.4, and 4.8). Patients &ge; 75 years in whom the benefit with prasugrel was more evident included those with diabetes, STEMI, higher risk of stent thrombosis, or recurrent events.</p><p>Patients with a history of TIA or a history of ischaemic stroke more than 3 months prior to prasugrel therapy had no reduction in the primary composite endpoint.</p><p>&nbsp;</p><p><strong>Table 3: Patients with Outcome Events in TRITON Primary Analysis</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:691px"><tbody><tr><td style="vertical-align:bottom"><p><strong>Outcome Events</strong></p></td><td style="vertical-align:top"><p><strong>Prasugrel</strong></p><p><strong>+ ASA</strong></p></td><td style="vertical-align:top"><p><strong>Clopidogrel</strong></p><p><strong>+ASA</strong></p></td><td style="vertical-align:top"><p><strong>Hazard Ratio (HR)</strong></p><p><strong>(95% CI)</strong></p></td><td style="vertical-align:top"><p><strong>p-value</strong></p></td></tr><tr><td style="vertical-align:bottom"><p><strong>All ACS</strong></p></td><td style="vertical-align:top"><p><strong>(N = 6813)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>(N = 6795)</strong></p><p><strong>%</strong></p></td><td rowspan="2"><p>0.812 (0.732, 0.902)</p></td><td rowspan="2"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p><strong>Primary Composite Outcome Events</strong></p><p>Cardiovascular (CV) death, non fatal MI, or non fatal stroke</p></td><td style="vertical-align:top"><p>9.4</p></td><td style="vertical-align:top"><p>11.5</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Primary Individual Outcome Events</strong></p></td></tr><tr><td style="vertical-align:top"><p>CV death</p></td><td style="vertical-align:top"><p>2.0</p></td><td style="vertical-align:top"><p>2.2</p></td><td style="vertical-align:top"><p>0.886 (0.701, 1.118)</p></td><td style="vertical-align:top"><p>0.307</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal MI</p></td><td style="vertical-align:top"><p>7.0</p></td><td style="vertical-align:top"><p>9.1</p></td><td style="vertical-align:top"><p>0.757 (0.672, 0.853)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal stroke</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>0.9</p></td><td style="vertical-align:top"><p>1.016 (0.712, 1.451)</p></td><td style="vertical-align:top"><p>0.930</p></td></tr><tr><td style="vertical-align:top"><p><strong>UA/NSTEMI</strong></p><p><strong>Primary Composite Outcome Events</strong></p></td><td style="vertical-align:top"><p><strong>(N = 5044)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>(N = 5030)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>CV death, nonfatal MI, or nonfatal stroke</p></td><td style="vertical-align:top"><p>9.3</p></td><td style="vertical-align:top"><p>11.2</p></td><td style="vertical-align:top"><p>0.820 (0.726, 0.927)</p></td><td style="vertical-align:top"><p>0.002</p></td></tr><tr><td style="vertical-align:top"><p>CV death</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>1.8</p></td><td style="vertical-align:top"><p>0.979 (0.732,1.309)</p></td><td style="vertical-align:top"><p>0.885</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal MI</p></td><td style="vertical-align:top"><p>7.1</p></td><td style="vertical-align:top"><p>9.2</p></td><td style="vertical-align:top"><p>0.761 (0.663,0.873)</p></td><td style="vertical-align:top"><p>&lt; 0.001</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal stroke</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.8</p></td><td style="vertical-align:top"><p>0.979 (0.633,1.513)</p></td><td style="vertical-align:top"><p>0.922</p></td></tr><tr><td style="vertical-align:top"><p><strong>STEMI</strong></p><p><strong>Primary Composite Outcome Events</strong></p></td><td style="vertical-align:top"><p><strong>(N = 1769)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top"><p><strong>(N = 1765)</strong></p><p><strong>%</strong></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>CV death, nonfatal MI, or nonfatal stroke</p></td><td style="vertical-align:top"><p>9.8</p></td><td style="vertical-align:top"><p>12.2</p></td><td style="vertical-align:top"><p>0.793 (0.649, 0.968)</p></td><td style="vertical-align:top"><p>0.019</p></td></tr><tr><td style="vertical-align:top"><p>CV death</p></td><td style="vertical-align:top"><p>2.4</p></td><td style="vertical-align:top"><p>3.3</p></td><td style="vertical-align:top"><p>0.738 (0.497,1.094)</p></td><td style="vertical-align:top"><p>0.129</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal MI</p></td><td style="vertical-align:top"><p>6.7</p></td><td style="vertical-align:top"><p>8.8</p></td><td style="vertical-align:top"><p>0.746 (0.588,0.948)</p></td><td style="vertical-align:top"><p>0.016</p></td></tr><tr><td style="vertical-align:top"><p>Nonfatal stroke</p></td><td style="vertical-align:top"><p>1.2</p></td><td style="vertical-align:top"><p>1.1</p></td><td style="vertical-align:top"><p>1.097 (0.590,2.040)</p></td><td style="vertical-align:top"><p>0.770</p></td></tr></tbody></table><p>In the All ACS population, analysis of each of the secondary endpoints showed a significant benefit (p &lt; 0.001) for prasugrel versus clopidogrel. These included definite or probable stent thrombosis at study end (0.9% vs 1.8%; HR 0.498; CI 0.364, 0.683); CV death, nonfatal MI, or urgent target vessel revascularization through 30 days (5.9% vs 7.4%; HR 0.784; CI 0.688,0.894); all cause death, nonfatal MI, or nonfatal stroke through study end (10.2% vs 12.1%; HR 0.831; CI 0.751, 0.919); CV death, nonfatal MI, nonfatal stroke or prehospitalization for cardiac ischaemic event through study end (11.7% vs 13.8%; HR 0.838; CI 0.762, 0.921). Analysis of all cause death did not show any significant difference between prasugrel and clopidogrel in the All ACS population (2.76% vs 2.90%), in the UA/NSTEMI population (2.58% vs 2.41%), and in the STEMI population (3.28% vs 4.31%).</p><p>Prasugrel was associated with a 50% reduction in stent thrombosis through the 15 month follow-up period. The reduction in stent thrombosis with Pevas was observed both early and beyond 30 days for both bare metal and drug eluting stents.</p><p>In an analysis of patients who survived an ischaemic event, prasugrel was associated with a reduction in the incidence of subsequent primary endpoint events (7.8% for prasugrel vs 11.9% for clopidogrel).</p><p>Although bleeding was increased with prasugrel, an analysis of the composite endpoint of death from any cause, nonfatal myocardial infarction, nonfatal stroke, and non-CABG-related TIMI major haemorrhage favoured Pevas compared to clopidogrel (Hazard ratio, 0.87; 95% CI, 0.79 to 0.95; p = 0.004). In TRITON, for every 1000 patients treated with Pevas, there were 22 fewer patients with myocardial infarction, and 5 more with non&ndash;CABG-related TIMI major haemorrhages, compared with patients treated with clopidogrel.</p><p>Results of a pharmacodynamic/pharmacogenomic study in 720 Asian ACS PCI patients demonstrated that higher levels of platelet inhibition are achieved with prasugrel compared to clopidogrel, and that prasugrel 60-mg loading dose/10-mg maintenance dose is an appropriate dose regimen in Asian subjects who weigh at least 60 kg and are less than 75 years of age (see section 4.2).</p><p>&nbsp;</p><p>In a 30 month study (TRILOGY&ndash;ACS) in 9326 patients with UA/NSTEMI ACS medically managed without revascularisation (non-licensed indication), prasugrel did not significantly reduce the frequency of the composite endpoint of CV death, MI or stroke compared to clopidogrel. Rates of TIMI major bleeding (including life threatening, fatal and ICH) were similar in prasugrel and clopidogrel treated patients. Patients &ge;75 years old or those below 60 kg (N=3022) were randomized to 5 mg prasugrel. As in the &lt; 75 years old and &ge;60 kg patients treated with 10 mg prasugrel, there was no difference between 5 mg prasugrel and 75 mg clopidogrel in CV outcomes. Rates of major bleeding were similar in patients treated with 5 mg prasugrel and those treated with 75 mg clopidogrel. Prasugrel 5 mg provided greater antiplatelet effect than clopidogrel 75 mg. Prasugrel should be used with caution in patients &ge; 75 years old and in patients weighing &lt;60 kg (see sections 4.2, 4.4 and 4.8).</p><p>In a 30-day study (ACCOAST) in 4033 patients with NSTEMI with elevated troponin who were scheduled for coronary angiography followed by PCI within 2 to 48 hours after randomization, subjects who received prasugrel 30 mg loading dose on average 4 hours prior to coronary angiography followed by a 30 mg loading dose at the time of PCI (n=2037) had an increased risk of non-CABG peri-procedural bleeding and no additional benefit compared to patients receiving a 60 mg loading dose at the time of PCI (n=1996). Specifically, prasugrel did not significantly reduce the frequency of the composite endpoint of cardiovascular (CV) death, myocardial infarction (MI), stroke, urgent revascularization (UR), or glycoprotein (GP) IIb/IIIa inhibitor bailout through 7 days from randomization in subjects receiving prasugrel prior to coronary angiography compared to patients receiving the full loading dose of prasugrel at the time of PCI, and the rate of the key safety objective for all TIMI major bleeding (CABG and non-CABG events) through 7 days from randomization in all treated subjects was significantly higher in subjects receiving prasugrel prior to coronary angiography versus patients receiving the full loading dose of prasugrel at the time of PCI. Therefore, in UA/NSTEMI patients, where coronary angiography is performed within 48 hours after admission, the loading dose should be given at the time of PCI. (See sections 4.2, 4.4, and 4.8)</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>Study TADO tested the use of prasugrel (n=171) vs placebo (n=170) in patients, ages 2 to less than 18 years of age, with sickle cell anaemia for reduction of vaso occlusive crisis in a phase III study. The study failed to meet any of the primary or secondary endpoints. Overall, no new safety findings were identified for prasugrel as monotherapy in this patient population.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Prasugrel is a prodrug and is rapidly metabolized&nbsp;in vivo&nbsp;to an active metabolite and inactive metabolites. The active metabolite&#39;s exposure (AUC) has moderate to low between-subject (27%) and within-subject (19%) variability. Prasugrel&#39;s pharmacokinetics are similar in healthy subjects, patients with stable atherosclerosis, and patients undergoing percutaneous coronary intervention.</p><p><u>Absorption</u></p><p>The absorption and metabolism of prasugrel are rapid, with peak plasma concentration (C<sub>max</sub>) of the active metabolite occurring in approximately 30 minutes. The active metabolite&#39;s exposure (AUC) increases proportionally over the therapeutic dose range. In a study of healthy subjects, AUC of the active metabolite was unaffected by a high fat, high calorie meal, but C<sub>max</sub>&nbsp;was decreased by 49% and the time to reach C<sub>max</sub>&nbsp;(T<sub>max</sub>) was increased from 0.5 to 1.5 hours. Pevas was administered without regard to food in TRITON. Therefore, Pevas can be administered without regard to food; however, the administration of prasugrel loading dose in the fasted state may provide most rapid onset of action (see section 4.2).</p><p><u>Distribution</u></p><p>Active metabolite binding to human serum albumin (4% buffered solution) was 98%.</p><p><u>Biotransformation</u></p><p>Prasugrel is not detected in plasma following oral administration. It is rapidly hydrolysed in the intestine to a thiolactone, which is then converted to the active metabolite by a single step of cytochrome P450 metabolism, primarily by CYP3A4 and CYP2B6 and to a lesser extent by CYP2C9 and CYP2C19. The active metabolite is further metabolized to two inactive compounds by S-methylation or conjugation with cysteine.</p><p>In healthy subjects, patients with stable atherosclerosis, and patients with ACS receiving Pevas, there was no relevant effect of genetic variation in CYP3A5, CYP2B6, CYP2C9, or CYP2C19 on the pharmacokinetics of prasugrel or its inhibition of platelet aggregation.</p><p><u>Elimination</u></p><p>Approximately 68% of the prasugrel dose is excreted in the urine and 27% in the faeces, as inactive metabolites. The active metabolite has an elimination half-life of about 7.4 hours (range 2 to 15 hours).</p><p><u>Pharmacokinetics in special Populations</u></p><p>Elderly:</p><p>In a study of healthy subjects between the ages of 20 and 80 years, age had no significant effect on pharmacokinetics of prasugrel or its inhibition of platelet aggregation. In the large phase 3 clinical trial, the mean estimated exposure (AUC) of the active metabolite was 19% higher in very elderly patients (&ge; 75 years of age) compared to subjects &lt; 75 years of age. Prasugrel should be used with caution in patients &ge; 75 years of age due to the potential risk of bleeding in this population (see sections 4.2 and 4.4). In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients &ge;75 years old taking 5 mg prasugrel was approximately half that in patients &lt; 65 years old taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was reduced but was non-inferior compared to 10 mg.</p><p><u>Hepatic impairment:</u></p><p>No dose adjustment is necessary for patients with mild to moderate impaired hepatic function (Child Pugh Class A and B). Pharmacokinetics of prasugrel and its inhibition of platelet aggregation were similar in subjects with mild to moderate hepatic impairment compared to healthy subjects. Pharmacokinetics and pharmacodynamics of prasugrel in patients with severe hepatic impairment have not been studied. Prasugrel must not be used in patients with severe hepatic impairment (see section 4. 3).</p><p><u>Renal impairment:</u></p><p>No dosage adjustment is necessary for patients with renal impairment, including patients with end stage renal disease (ESRD). Pharmacokinetics of prasugrel and its inhibition of platelet aggregation are similar in patients with moderate renal impairment (GFR 30&lt;50 ml/min/1.73m<sup>2</sup>) and healthy subjects. Prasugrel-mediated inhibition of platelet aggregation was also similar in patients with ESRD who required haemodialysis compared to healthy subjects, although C<sub>max</sub>&nbsp;and AUC of the active metabolite decreased 51% and 42%, respectively, in ESRD patients.</p><p><u>Body weight:</u></p><p>The mean exposure (AUC) of the active metabolite of prasugrel is approximately 30 to 40% higher in healthy subjects and patients with a body weight of &lt; 60 kg compared to those weighing &ge; 60 kg. Prasugrel should be used with caution in patients with a body weight of &lt; 60 kg due to the potential risk of bleeding in this population (see section 4.4). In a study in subjects with stable atherosclerosis, the mean AUC of the active metabolite in patients &lt;60 kg taking 5 mg prasugrel was 38% lower than in patients &ge;60 kg taking 10 mg prasugrel, and the antiplatelet effect of 5 mg was similar to 10 mg.</p><p><u>Ethnicity:</u></p><p>In clinical pharmacology studies, after adjusting for body weight, the AUC of the active metabolite was approximately 19% higher in Chinese, Japanese, and Korean subjects compared to that of Caucasians, predominantly related to higher exposure in Asian subjects &lt; 60 kg. There is no difference in exposure among Chinese, Japanese, and Korean subjects. Exposure in subjects of African and Hispanic descent is comparable to that of Caucasians. No dose adjustment is recommended based on ethnicity alone.</p><p><u>Gender</u>:</p><p>In healthy subjects and patients, the pharmacokinetics of prasugrel are similar in men and women.</p><p><u>Paediatric population:</u></p><p>Pharmacokinetics and pharmacodynamics of prasugrel have not been evaluated in a paediatric population (see section 4.2).</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Non-clinical data reveal no special hazard for humans based on conventional studies of safety pharmacology, repeat-dose toxicity, genotoxicity, carcinogenic potential, or toxicity to reproduction. Effects in non-clinical studies were observed only at exposures considered sufficiently in excess of the maximum human exposure indicating little relevance to clinical use.</p><p>Embryo-fetal developmental toxicology studies in rats and rabbits showed no evidence of malformations due to prasugrel. At a very high dose (&gt; 240 times the recommended daily human maintenance dose on a mg/m<sup>2</sup>&nbsp;basis) that caused effects on maternal body weight and/or food consumption, there was a slight decrease in offspring body weight (relative to controls). In pre- and post-natal rat studies, maternal treatment had no effect on the behavioural or reproductive development of the offspring at doses up to an exposure 240 times the recommended daily human maintenance dose (based on mg/m<sup>2</sup>).</p><p>No compound-related tumors were observed in a 2-year rat study with prasugrel exposures ranging to greater than 75 times the recommended therapeutic exposures in humans (based on plasma exposures to the active and major circulating human metabolites). There was an increased incidence of tumors (hepatocellular adenomas) in mice exposed for 2 years to high doses (&gt; 75 times human exposure), but this was considered secondary to prasugrel-induced enzyme-induction. The rodent-specific association of liver tumors and drug-induced enzyme induction is well documented in the literature. The increase in liver tumors with prasugrel administration in mice is not considered a relevant human risk.</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Tablet Core:</p><p>Microcrystalline cellulose</p><p>Spray Dried Mannitol</p><p>Croscarmellose sodium</p><p>hydroxypropyl methylcellulose 5cp</p><p>Magnesium stearate</p><p>Film-Coat:</p><p>opadry White OYL 28900</p><p>Iron oxide red (E172) {only Pevas 10 mg}</p><p>Iron oxide yellow (E172)</p><p>Talc</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.


            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C.</p><p>Store in the original package in order to protect from air and moisture<strong> .</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>blisters in cartons of 30 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                MS Pharma Saudi,
Grand center 1st floor,
Alrabiea area - King Abdulaziz Road,
Riyadh, Kingdome Saudi Arabia
P.O.Box 54850
Phone: +966112790122
RegulatoryKSA@mspharma.com

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Mar-19
SPC-002-0319-00

            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>